Skip to content

Comparison of clinical, pathological, immunological, and prognostic characteristics in patients with metabolic dysfunction-associated steatotic liver disease- related hepatocellular carcinoma and hepatitis B virus- related hepatocellular carcinoma who underwent hepatectomy: a multicenter study

Comparison of clinical, pathological, immunological, and prognostic characteristics in patients with metabolic dysfunction-associated steatotic liver disease- related hepatocellular carcinoma and hepatitis B virus- related hepatocellular carcinoma who underwent hepatectomy: a multicenter study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106719
Enrollment
Unknown
Registered
2025-07-29
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Adult (>=18 years old); 2. The patient underwent liver cancer resection surgery at our hospital; 3. The patient was diagnosed with pure MAFLD HCC and mixed MAFLD and HBV HCC; The diagnostic criteria for MAFLD are: Overweight or obesity: defined as Caucasian BMI>=25kg/m ^ 2 or Asian BMI>=23kg/m ^ 2. Thin/Normal Weight: White BMI=102/88 cm (or Asian males and females>=90/80 cm) Blood pressure>=130/85 mmHg or receiving specific medication treatment Plasma triglycerides>=150 mg/dL (>=1.70 mmol/l) or specific drug therapy Plasma HDL cholesterol: Male=2.5 Plasma high-sensitivity C-reactive protein (hs CRP) level>2 mg/L Having 1 or 3 can be diagnosed as MAFLD. Having at least two metabolic abnormality risk factors can also be diagnosed as MAFLD. 4. Child Pugh classification of liver function: A or B grade; 5. No severe cardiovascular or renal dysfunction; 6. Having detailed preoperative clinical features, prognostic data, and pathological tissue specimens.

Exclusion criteria

Exclusion criteria: 1. Merge with other malignant tumors; 2. Metastatic liver cancer; 3. Tumor recurrence and subsequent resection; 4. Accidental death due to other illnesses.

Design outcomes

Primary

MeasureTime frame
overall survival;progression free survival;

Countries

China

Contacts

Public ContactYin Xin

Zhongshan Hospital, Fudan University

yin.xin@zs-hospital.sh.cn+86 139 1845 7694

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026